Complete both scorecards to calculate your growth score.
—Overall growth scoreupdated
Funnel
Acquire
Activate
Coming soon
Monetize
Coming soon
Retain / Reengage
Coming soon
Graded against Lazyweb’s growth rubrics.
Lazyweb
Your landing page’s weakest score is Trust.
How LionBio Therapeutics ranks
- 1.
LionBio Therapeutics75
- 2.
Rani Therapeutics74
- 3.
Entera Bio61
- 4.
Structure Therapeutics53
- 5.
Oramed Pharmaceuticals48
75Growth scoreupdated
category scores
category scoresShowHide
Score over time
Trust
64FairProof that the product is real, competent, and safe to try.
| Trust read | |
|---|---|
| LionBio Therapeutics | "Columbia — University spinout technology" credential in the stats strip |
| "3 Phase 1 studies completed" stat badge | |
| No visible trust signal identified. | |
| No visible trust signal identified. | |
| No visible trust signal identified. |
Information hierarchy
73FairDoes the design help or inhibit what the page is trying to say?
123- Explore our research — Dark green on black hero gives the primary CTA the lowest contrast of any button on the page.
- View open roles — White secondary button outshines the primary CTA at equal size, splitting the click between two actions.
- Careers nav pill — Reuses the primary CTA's green fill, pulling first-glance attention to the top-right exit.
CTA
76FairCopy, size, verb, cost-feel — does the primary CTA earn the click?
Problems
- 'Explore' is a soft, vague verb
- no header echo of GLP-1 hook
- payoff of the click is unclear
Mobile web
78FairThe phone experience as a first-class citizen.
1234- Top nav link row — Desktop pill links (Team/Research/Blog/Careers) are crammed in uncollapsed instead of a hamburger menu.
- Explore our research button — Primary CTA floats at roughly half the column width instead of a full-bleed, thumb-friendly bar.
- Hero headline — Serif headline scales up too far, wrapping into four lines and eating a quarter of the fold.
- View open roles button — Secondary CTA is styled at near-equal weight and stacks directly under the primary, splitting the tap decision.
Value props
82StrongTitle, subtitle, hero — do they sell the product's true value?
LionBio Therapeutics’s headline sells
The world's first GLP-1s taken through your nose.
Direct-to-brain and less nausea. Next gen intranasal peptide therapeutics powered by our precision nanoparticle technology.
Working
- World-first claim is concrete and instantly parseable
- 'Less nausea' targets the category's real pain point
- 30+ years IP and Columbia spinout add credibility
Could improve
- 'Less nausea' has no supporting number
- Hero render decorates, doesn't show mechanism
- No development stage or trial status shown
Competitors
closest by platform, customer profile, and value propGraded against Lazyweb’s growth rubrics.
SEO / AEO · lion.bio
Unlock SEO / AEO
See your search and AI visibility, agent readiness score, and prioritized fixes with Lazyweb Pro.
Try Pro Free